Molecular Cancer Therapeutics

Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts.

First-in-Human Study of ABY-029, a Novel Fluorescent Peptide that Targets EGFR, Applied to Soft-Tissue Sarcomas.

Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma.

G2/M期激酶的激酶组重编程和MYCN的抑制有助于洛拉替尼在ALK驱动的神经母细胞瘤中发挥更优异的疗效

KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors.

KT-253 是一种新型 MDM2 降解剂和 p53 稳定剂，其效力和功效优于 MDM2 小分子抑制剂

Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer.

利鲁唑通过激活结直肠癌中的 cGAS/STING 信号通路增强抗 PD-1 疗效

A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors.

IL-12锚定药物偶联物治疗实体瘤的药代动力学和药效学模型

STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition.

STAT5 激活通过阻止 PD-1 抑制来增强过继疗法与肽疫苗联合应用的效果

Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control.

肿瘤整合素靶向葡萄糖氧化酶促进ROS介导的细胞死亡，与干扰素α疗法联合用于肿瘤控制

A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies.

新型 B7-H4xCD3 双特异性 T 细胞衔接器 (PF-07260437) 与乳腺癌标准疗法和免疫检查点疗法具有协同作用

LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers.

LIG1 是 BRCA1 突变癌症中的合成致死靶点